Inventor · disambiguated record
Vincent C. O. Njar
Also filed as: NJAR VINCENT · NJAR VINCENT C O
22 granted patents·15 pending applications·195 citations·filing 1997–2023
95Inventor score
Files withUNIV MARYLAND18BRODIE ANGELA8NJAR VINCENT C O3TOKAI PHARMACEUTICALS INC2UNIV OF MARYLAND EASTERN SHORE2
Top patents by PatentIndex Score
37 records- 0192US7875599B2C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activityUNIV MARYLAND·Filed 2006·Granted Jan 25, 2011·21 cites·17 claims
- 0291US9018198B2Prodrugs of C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activityUNIV MARYLAND·Filed 2014·Granted Apr 28, 2015·7 cites·20 claims
- 0391US6444683B217-azolyl steroids useful as androgen synthesis inhibitorsUNIV MARYLAND·Filed 2000·Granted Sep 3, 2002·30 cites·10 claims
- 0488US7960435B2Anti-cancer agents and androgen inhibition activity compoundUNIV MARYLAND·Filed 2007·Granted Jun 14, 2011·9 cites·7 claims
- 0587US9295679B2Prodrugs of C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activityUNIV MARYLAND·Filed 2015·Granted Mar 29, 2016·3 cites·12 claims
- 0685US9387216B2Biomarkers for treatment of neoplastic disorders using androgen-targeted therapiesTOKAI PHARMACEUTICALS INC·Filed 2015·Granted Jul 12, 2016·9 cites·30 claims
- 0785US8785423B2Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseasesNJAR VINCENT·Filed 2009·Granted Jul 22, 2014·7 cites·8 claims
- 0883US8110550B2HDAC inhibitors and hormone targeted drugs for the treatment of cancerBRODIE ANGELA·Filed 2008·Granted Feb 7, 2012·8 cites·16 claims
- 0982US5994335A17-azolyl steroids useful as androgen synthesis inhibitorsUNIV MARYLAND·Filed 1997·Granted Nov 30, 1999·47 cites·59 claims
- 1079US9439912B2Androgen receptor down-regulating agents and uses thereofUNIV OF MARYLAND EASTERN SHORE·Filed 2015·Granted Sep 13, 2016·5 cites·8 claims
- 1175US2010137269A1Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens: Synehesis, In Vitro Biological Activities, Pharmacokinetics and Antitumor ActivityBRODIE ANGELA·Filed 2009·Application pending·0 cites
- 1272US7265143B2C-4 substituted retinoidsUNIV MARYLAND·Filed 2003·Granted Sep 4, 2007·10 cites·37 claims
- 1372US6200965B117-Azolyl steroids useful as androgren synthesis inhibitorsUNIV MARYLSND BALTIMORE·Filed 1999·Granted Mar 13, 2001·33 cites·7 claims
- 1471US10793525B213-cis-RAMBA retinamides that degrade MNKs for treating cancerUNIV MARYLAND·Filed 2015·Granted Oct 6, 2020·2 cites·26 claims
- 1571US9156792B2Retinamide and uses thereofNJAR VINCENT C O·Filed 2009·Granted Oct 13, 2015·2 cites·19 claims
- 1671US2011118219A1Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activityUNIV MARYLAND·Filed 2009·Application pending·0 cites
- 1768US10098896B2C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activityTHE UNIV OF MARYLAND BALTIMORE·Filed 2016·Granted Oct 16, 2018·0 cites·6 claims
- 1867US9808472B2Biomarkers for treatment of neoplastic disorders using androgen-targeted therapiesTOKAI PHARMACEUTICALS INC·Filed 2014·Granted Nov 7, 2017·1 cites·4 claims
- 1967US2014288036A1Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activityUNIV MARYLAND·Filed 2013·Application pending·0 cites
- 2065US2010048524A1Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor ActivityBRODIE ANGELA·Filed 2009·Application pending·0 cites
- 2165US2010048914A1Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor ActivityBRODIE ANGELA·Filed 2009·Application pending·0 cites
- 2264US9884067B2Androgen receptor down-regulating agents and uses thereofUNIV OF MARYLAND EASTERN SHORE·Filed 2014·Granted Feb 6, 2018·1 cites·13 claims
- 2364US2010048912A1Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor ActivityBRODIE ANGELA·Filed 2009·Application pending·0 cites
- 2464US2010047338A1Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor ActivityBRODIE ANGELA·Filed 2009·Application pending·0 cites
- 2564US2010048913A1Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor ActivityBRODIE ANGELA·Filed 2009·Application pending·0 cites
- 2659US11707468B2Methods of treating pancreatic cancerUNIV MARYLAND·Filed 2020·Granted Jul 25, 2023·0 cites·14 claims
- 2759US2011105445A1Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancerUNIV MARYLAND·Filed 2009·Application pending·0 cites
- 2855US10675289B2Methods of treating pancreatic cancerUNIV MARYLAND·Filed 2015·Granted Jun 9, 2020·0 cites·20 claims
- 2955US10617685B2Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activityUNIV MARYLAND·Filed 2017·Granted Apr 14, 2020·0 cites·14 claims
- 3055US9694005B2Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activityUNIV MARYLAND·Filed 2014·Granted Jul 4, 2017·0 cites·10 claims
- 3149US2015209379A1Treatment of prostate cancer and hematologic neoplasmsUNIV JEFFERSON·Filed 2013·Application pending·0 cites
- 3248US2025179029A1Deuterated retinoidal compounds and synthesis and uses thereofUNIV MARYLAND·Filed 2023·Application pending·0 cites
- 3347US2012108522A1Hdac inhibitors and hormone targeted drugs for the treatment of cancerBRODIE ANGELA·Filed 2012·Application pending·0 cites
- 3446US2012122908A1Novel C-4 Substituted RetinoidsNJAR VINCENT C O·Filed 2007·Application pending·0 cites
- 3542US2015297615A1Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancerUNIV MARYLAND·Filed 2015·Application pending·0 cites
- 3642US2010184812A1Mutual prodrugs and methods to treat cancerUNIV MARYLAND·Filed 2008·Application pending·0 cites
- 3724US12391725B2Method for production of novel galeterone analogs and uses thereofNJAR VINCENT C O·Filed 2017·Granted Aug 19, 2025·0 cites·7 claims
Join the waitlist — get patent alerts
Get an alert when Vincent C. O. Njar files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →